Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma

Molecular and Cellular Proteomics

Volumn 13, Issue 3, 2014, Pages 701-715

  Mundt, Filip ^a   Johansson, Henrik J ^a   Forshed, Jenny ^a   Arslan, Sertaç ^b   Metintas, Muzaffer ^b   Dobra, Katalin ^a   Lehtiö, Janne ^a   Hjerpe, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; APOLIPOPROTEIN C1; BLOOD CLOTTING FACTOR 12; CERULOPLASMIN; COLLAGEN TYPE 6; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C8; COMPLEMENT COMPONENT C9; DESMOGLEIN 2; GALECTIN 1; INTERCELLULAR ADHESION MOLECULE 1; LAMININ ALPHA4; MANGANESE SUPEROXIDE DISMUTASE; MYOSIN; MYOSIN VIIB; NEUROPILIN 1; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SCATTER FACTOR; SEPTIN; SYNDECAN 1; TENASCIN; THROMBOSPONDIN; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR POU4F3; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CANCER PROGNOSIS; CLINICAL ARTICLE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ISOELECTRIC FOCUSING; LIQUID CHROMATOGRAPHY; LUNG ADENOCARCINOMA; MALE; MALIGNANT MESOTHELIOMA; MASS SPECTROMETRY; METASTASIS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEOMICS;

AGED; AGED, 80 AND OVER; COMPUTATIONAL BIOLOGY; DISCRIMINANT ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GALECTIN 1; HUMANS; KAPLAN-MEIER ESTIMATE; LEAST-SQUARES ANALYSIS; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MESOTHELIOMA; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; PLEURAL EFFUSION; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84895548847     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M113.030775     Document Type: Article

References (80)

1. Antman, K., Shemin, R., Ryan, L., Klegar, K., Osteen, R., Herman, T., Lederman, G., and Corson, J. (1988) Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J. Clin. Oncol. 6, 147-153
2. Sterman, D. H., and Albelda, S. M. (2005) Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 10, 266-283
3. Chang, K., and Pastan, I. (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. U.S.A. 93, 136-140
4. Creaney, J., Yeoman, D., Demelker, Y., Segal, A., Musk, A. W., Skates, S. J., and Robinson, B. W. (2008) Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J. Thorac. Oncol. 3, 851-857
5. Scherpereel, A., Grigoriu, B., Conti, M., Gey, T., Gregoire, M., Copin, M. C., Devos, P., Chahine, B., Porte, H., and Lassalle, P. (2006) Soluble mesothelin- related peptides in the diagnosis of malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 173, 1155-1160
6. Robinson, B. W., Creaney, J., Lake, R., Nowak, A., Musk, A. W., de Klerk, N., Winzell, P., Hellstrom, K. E., and Hellstrom, I. (2003) Mesothelinfamily proteins and diagnosis of mesothelioma. Lancet 362, 1612-1616
7. Grigoriu, B., Chahine, B., Zerimech, F., Gregoire, M., Balduyck, M., Copin, M. C., Devos, P., Lassalle, P., and Scherpereel, A. (2009) Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin. Biochem. 42, 1046-1050
8. Creaney, J., Yeoman, D., Musk, A. W., de Klerk, N., Skates, S. J., and Robinson, B. W. (2011) Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma - which is best? Lung Cancer 74, 55-60
9. Onda, M., Nagata, S., Ho, M., Bera, T. K., Hassan, R., Alexander, R. H., and Pastan, I. (2006) Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin. Cancer Res. 12, 4225-4231
10. Shiomi, K., Miyamoto, H., Segawa, T., Hagiwara, Y., Ota, A., Maeda, M., Takahashi, K., Masuda, K., Sakao, Y., and Hino, O. (2006) Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci. 97, 928-932
11. Scholler, N., Fu, N., Yang, Y., Ye, Z., Goodman, G. E., Hellstrom, K. E., and Hellstrom, I. (1999) Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. U.S.A. 96, 11531-11536
12. Argani, P., Iacobuzio-Donahue, C., Ryu, B., Rosty, C., Goggins, M., Wilentz, R. E., Murugesan, S. R., Leach, S. D., Jaffee, E., Yeo, C. J., Cameron, J. L., Kern, S. E., and Hruban, R. H. (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 7, 3862-3868
13. Hollevoet, K., Bernard, D., De Geeter, F., Walgraeve, N., Van den Eeckhaut, A., Vanholder, R., Van de Wiele, C., Stove, V., van Meerbeeck, J. P., and Delanghe, J. R. (2009) Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin. Chem. 55, 1431-1433
14. Hollevoet, K., Nackaerts, K., Thas, O., Thimpont, J., Germonpre, P., De Vuyst, P., Bosquee, L., Legrand, C., Kellen, E., Kishi, Y., Delanghe, J. R., and van Meerbeeck, J. P. (2011) The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest 141, 477-484
15. Shiomi, K., Shiomi, S., Ishinaga, Y., Sakuraba, M., Hagiwara, Y., Miyashita, K., Maeda, M., Suzuki, K., Takahashi, K., and Hino, O. (2011) Impact of renal failure on the tumor markers of mesothelioma, N-ERC/mesothelin and osteopontin. Anticancer Res. 31, 1427-1430
16. Meyer, K., and Chaffee, E. (1940) Hyaluronic acid in the pleural fluid associated with a malignant tumor involving the pleura and peritoneum. J. Biol. Chem. 133, 83-91
17. Blix, G. (1951) Hyaluronic acid in the pleural and peritoneal fluids from a case of mesothelioma. Acta Soc. Med. Ups. 56, 47-50
18. Harington, J. S., Wagner, J. C., and Smith, M. (1963) The detection of hyaluronic acid in pleural fluids of cases with diffuse pleural mesotheliomas. Br. J. Exp. Pathol. 44, 81-83
19. Friman, C., Hellstrom, P. E., Juvani, M., and Riska, H. (1977) Acid glycosaminoglycans (mucopolysaccharides) in the differential diagnosis of pleural effusion. Clin. Chim. Acta 76, 357-361
20. Havez, R., Degand, P., Boersma, A., and Richet, C. (1971) [Detection and estimation of hyaluronic acid in the pleural fluid of mesothelioma]. Clin. Chim. Acta 33, 443-454
21. Hjerpe, A. (1986) Liquid-chromatographic determination of hyaluronic acid in pleural and ascitic fluids. Clin. Chem. 32, 952-956
22. Nurminen, M., Dejmek, A., Martensson, G., Thylen, A., and Hjerpe, A. (1994) Clinical utility of liquid-chromatographic analysis of effusions for hyaluronate content. Clin. Chem. 40, 777-780
23. Martensson, G., Thylen, A., Lindquist, U., and Hjerpe, A. (1994) The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods. Cancer 73, 1406-1410
24. Thylen, A., Levin-Jacobsen, A. M., Hjerpe, A., and Martensson, G. (1997) Immunohistochemical differences between hyaluronan- and non-hyaluronan- producing malignant mesothelioma. Eur. Resp. J. 10, 404-408
25. Welker, L., Muller, M., Holz, O., Vollmer, E., Magnussen, H., and Jorres, R. A. (2007) Cytological diagnosis of malignant mesothelioma - improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch. 450, 455-461
26. Pass, H. I., Liu, Z., Wali, A., Bueno, R., Land, S., Lott, D., Siddiq, F., Lonardo, F., Carbone, M., and Draghici, S. (2004) Gene expression profiles predict survival and progression of pleural mesothelioma. Clin. Cancer Res. 10, 849-859
27. Pass, H. I., Lott, D., Lonardo, F., Harbut, M., Liu, Z., Tang, N., Carbone, M., Webb, C., and Wali, A. (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl. J. Med. 353, 1564-1573
28. Grigoriu, B. D., Scherpereel, A., Devos, P., Chahine, B., Letourneux, M., Lebailly, P., Gregoire, M., Porte, H., Copin, M. C., and Lassalle, P. (2007) Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 13, 2928-2935
29. Paleari, L., Rotolo, N., Imperatori, A., Puzone, R., Sessa, F., Franzi, F., Meacci, E., Camplese, P., Cesario, A., and Paganuzzi, M. (2009) Osteopontin is not a specific marker in malignant pleural mesothelioma. Int. J. Biol. Markers 24, 112-117
30. Hegmans, J. P., Veltman, J. D., Fung, E. T., Verch, T., Glover, C., Zhang, F., Allard, W. J., T'Jampens, D., Hoogsteden, H. C., Lambrecht, B. N., and Aerts, J. (2009) Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS. Technol. Cancer Res. Treat. 8, 323-332
31. Pass, H. I., Levin, S. M., Harbut, M. R., Melamed, J., Chiriboga, L., Donington, J., Huflejt, M., Carbone, M., Chia, D., Goodglick, L., Goodman, G. E., Thornquist, M. D., Liu, G., de Perrot, M., Tsao, M. S., and Goparaju, C. (2012) Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N. Engl. J. Med. 367, 1417-1427
32. Wisniewski, J. R., Zougman, A., Nagaraj, N., and Mann, M. (2009) Universal sample preparation method for proteome analysis. Nat. Methods 6, 359-362
33. Eriksson, H., Lengqvist, J., Hedlund, J., Uhlen, K., Orre, L. M., Bjellqvist, B., Persson, B., Lehtio, J., and Jakobsson, P. J. (2008) Quantitative mem brane proteomics applying narrow range peptide isoelectric focusing for studies of small cell lung cancer resistance mechanisms. Proteomics 8, 3008-3018
34. Lengqvist, J., Uhlen, K., and Lehtio, J. (2007) iTRAQ compatibility of peptide immobilized pH gradient isoelectric focusing. Proteomics 7, 1746-1752
35. Branca, R. M., Orre, L.-M., Johansson, H. J., Granholm, V., Huss, M., Pérez-Bercoff, Å., Forshed, J., Käll, L., and Lehtiö, J. (2013) HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat. Methods 11, 59-62
36. Vizcaino, J. A., Cote, R. G., Csordas, A., Dianes, J. A., Fabregat, A., Foster, J. M., Griss, J., Alpi, E., Birim, M., Contell, J., O'Kelly, G., Schoenegger, A., Ovelleiro, D., Perez-Riverol, Y., Reisinger, F., Rios, D., Wang, R., and Hermjakob, H. (2013) The PRoteomics IDEntifications (PRIDE) database and associated tools: Status in 2013. Nucleic Acids Res. 41, D1063-D1069
37. Tusher, V. G., Tibshirani, R., and Chu, G. (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. 98, 5116-5121
38. Hulsen, T., de Vlieg, J., and Alkema, W. (2008) BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics 9, 488
39. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57
40. Vergara, I. A., Norambuena, T., Ferrada, E., Slater, A. W., and Melo, F. (2008) StAR: A simple tool for the statistical comparison of ROC curves. BMC Bioinformatics 9, 265
41. Mundt, F., Nilsonne, G., Arslan, S., Csuros, K., Hillerdal, G., Yildirim, H., Metintas, M., Dobra, K., and Hjerpe, A. (2013) Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. PLoS One 8, e72030
42. Budczies, J., Klauschen, F., Sinn, B. V., Gyorffy, B., Schmitt, W. D., Darb-Esfahani, S., and Denkert, C. (2012) Cutoff Finder: A comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 7, e51862
43. Husain, A. N., Colby, T., Ordonez, N., Krausz, T., Attanoos, R., Beasley, M. B., Borczuk, A. C., Butnor, K., Cagle, P. T., Chirieac, L. R., Churg, A., Dacic, S., Fraire, A., Galateau-Salle, F., Gibbs, A., Gown, A., Hammar, S., Litzky, L., Marchevsky, A. M., Nicholson, A., Roggli, V., Travis, W. D., and Wick, M. (2012) Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch. Pathol. Lab. Med. 137, 647-667
44. Robinson, B. W., Musk, A. W., and Lake, R. A. (2005) Malignant mesothelioma. Lancet 366, 397-408
45. van der Bij, S., Schaake, E., Koffijberg, H., Burgers, J. A., de Mol, B. A., and Moons, K. G. (2011) Markers for the non-invasive diagnosis of mesothelioma: A systematic review. Br. J. Cancer 104, 1325-1333
46. Kao, S. C., Reid, G., van Zandwijk, N., Henderson, D. W., and Klebe, S. (2011) Molecular biomarkers in malignant mesothelioma: State of the art. Pathology 43, 201-212
47. Heintz, N. H., Janssen-Heininger, Y. M., and Mossman, B. T. (2010) Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am. J. Respir. Cell. Mol. Biol. 42, 133-139
48. Sandberg, A., Lindell, G., Kallstrom, B. N., Branca, R. M., Danielsson, K. G., Dahlberg, M., Larson, B., Forshed, J., and Lehtio, J. (2012) Tumor proteomics by multivariate analysis on individual pathway data for characterization of vulvar cancer phenotypes. Mol. Cell. Proteomics 11, M112.016998
49. Jaurand, M. C., and Fleury-Feith, J. (2005) Pathogenesis of malignant pleural mesothelioma. Respirology 10, 2-8
50. Nishikawa, M., Hashida, M., and Takakura, Y. (2009) Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv. Drug Deliv. Rev. 61, 319-326
51. Shiau, A. L., Teo, M. L., Chen, S. Y., Wang, C. R., Hsieh, J. L., Chang, M. Y., Chang, C. J., Chao, J., Chao, L., Wu, C. L., and Lee, C. H. (2010) Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer 10, 245
52. Ostroff, R. M., Mehan, M. R., Stewart, A., Ayers, D., Brody, E. N., Williams, S. A., Levin, S., Black, B., Harbut, M., Carbone, M., Goparaju, C., and Pass, H. I. (2012) Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One 7, e46091
53. Chong, H. C., Tan, C. K., Huang, R. L., and Tan, N. S. (2012) Matricellular proteins: A sticky affair with cancers. J. Oncol. 2012, 351089
54. Zanella, C. L., Posada, J., Tritton, T. R., and Mossman, B. T. (1996) Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res. 56, 5334-5338
55. Cermak, V., Kosla, J., Plachy, J., Trejbalova, K., Hejnar, J., and Dvorak, M. (2010) The transcription factor EGR1 regulates metastatic potential of v-src transformed sarcoma cells. Cell. Mol. Life Sci. 67, 3557-3568
56. Chiu, K. H., Chang, Y. H., Wu, Y. S., Lee, S. H., and Liao, P. C. (2011) Quantitative secretome analysis reveals that COL6A1 is a metastasisassociated protein using stacking gel-aided purification combined with iTRAQ labeling. J. Proteome Res. 10, 1110-1125
57. Cui, X., Song, B., Hou, L., Wei, Z., and Tang, J. (2008) High expression of osteoglycin decreases the metastatic capability of mouse hepatocarcinoma Hca-F cells to lymph nodes. Acta Biochim. Biophys. Sin. 40, 349-355
58. Cui, X. N., Tang, J. W., Song, B., Wang, B., Chen, S. Y., and Hou, L. (2009) High expression of osteoglycin decreases gelatinase activity of murine hepatocarcinoma Hca-F cells. World J. Gastroenterol. 15, 6117-6122
59. Ladhani, O., Sanchez-Martinez, C., Orgaz, J. L., Jimenez, B., and Volpert, O. V. (2011) Pigment epithelium-derived factor blocks tumor extravasation by suppressing amoeboid morphology and mesenchymal proteolysis. Neoplasia 13, 633-642
60. Merritt, R. E., Yamada, R. E., Wasif, N., Crystal, R. G., and Korst, R. J. (2004) Effect of inhibition of multiple steps of angiogenesis in syngeneic murine pleural mesothelioma. Ann. Thorac. Surg. 78, 1042-1051
61. Camby, I., Le Mercier, M., Lefranc, F., and Kiss, R. (2006) Galectin-1: A small protein with major functions. Glycobiology 16, 137R-157R
62. Kuo, P. L., Huang, M. S., Cheng, D. E., Hung, J. Y., Yang, C. J., and Chou, S. H. (2012) Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparinbinding EGF-like growth factor. J. Biol. Chem. 287, 9753-9764
63. Hsu, Y. L., Wu, C. Y., Hung, J. Y., Lin, Y. S., Huang, M. S., and Kuo, P. L. (2013) Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin alpha6beta4 and Notch1/Jagged2 signaling pathway. Carcinogenesis 34, 1370-1381
64. Szoke, T., Kayser, K., Baumhakel, J. D., Trojan, I., Furak, J., Tiszlavicz, L., Horvath, A., Szluha, K., Gabius, H. J., and Andre, S. (2005) Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer. Oncology 69, 167-174
65. Blanquart, C., Gueugnon, F., Nguyen, J. M., Roulois, D., Cellerin, L., Sagan, C., Perigaud, C., Scherpereel, A., and Gregoire, M. (2012) CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. J. Thorac. Oncol. 7, 883-889
66. Cao, D., Fan, S. T., and Chung, S. S. (1998) Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem. 273, 11429-11435
67. Scuric, Z., Stain, S. C., Anderson, W. F., and Hwang, J. J. (1998) New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 27, 943-950
68. Zhong, L., Shen, H., Huang, C., Jing, H., and Cao, D. (2011) AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. Toxicol. Appl. Pharmacol. 255, 40-47
69. Ma, J., Luo, D. X., Huang, C., Shen, Y., Bu, Y., Markwell, S., Gao, J., Liu, J., Zu, X., Cao, Z., Gao, Z., Lu, F., Liao, D. F., and Cao, D. (2012) AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker. Int. J. Cancer 131, E862-E871
70. Fukumoto, S., Yamauchi, N., Moriguchi, H., Hippo, Y., Watanabe, A., Shibahara, J., Taniguchi, H., Ishikawa, S., Ito, H., Yamamoto, S., Iwanari, H., Hironaka, M., Ishikawa, Y., Niki, T., Sohara, Y., Kodama, T., Nishimura, M., Fukayama, M., Dosaka-Akita, H., and Aburatani, H. (2005) Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin. Cancer Res. 11, 1776-1785
71. Balendiran, G. K. (2009) Fibrates in the chemical action of daunorubicin. Curr. Cancer Drug Targets 9, 366-369
72. Eads, F. E. (1951) The parenteral use of penicillin and streptomycin in complications of distemper. North Am. Vet. 32, 32-36
73. Matsunaga, T., Wada, Y., Endo, S., Soda, M., El-Kabbani, O., and Hara, A. (2012) Aldo-keto reductase 1B10 and its role in proliferation capacity of drug-resistant cancers. Front. Pharmacol. 3, 5
74. Hashimoto, Y., Imanishi, K., Tokui, N., Okamoto, T., Okamoto, A., Hatakeyama, S., Yoneyama, T., Koie, T., Kamimura, N., and Ohyama, C. (2011) Carboplatin-gemcitabine combination chemotherapy upregulates AKR1B10 expression in bladder cancer. Int. J. Clin. Oncol. 18, 177-182
75. Liu, Z., Yan, R., Al-Salman, A., Shen, Y., Bu, Y., Ma, J., Luo, D. X., Huang, C., Jiang, Y., Wilber, A., Mo, Y. Y., Huang, M. C., Zhao, Y., and Cao, D. (2012) Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells. Biochem. J. 442, 273-282
76. Vordermark, D., Said, H. M., Katzer, A., Kuhnt, T., Hansgen, G., Dunst, J., Flentje, M., and Bache, M. (2006) Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 6, 207
77. Rabinovich, G. A., Gabrilovich, D., and Sotomayor, E. M. (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296
78. Giachelli, C. M., Bae, N., Almeida, M., Denhardt, D. T., Alpers, C. E., and Schwartz, S. M. (1993) Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest. 92, 1686-1696
79. Martin-Manso, G., Galli, S., Ridnour, L. A., Tsokos, M., Wink, D. A., and Roberts, D. D. (2008) Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res. 68, 7090-7099
80. Lawler, J. (2002) Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell. Mol. Med. 6, 1-12